EP1003530A4 - Synthetische schildrüssenhormone enthaltende zusammensetzungen zur augenbehandlung - Google Patents

Synthetische schildrüssenhormone enthaltende zusammensetzungen zur augenbehandlung

Info

Publication number
EP1003530A4
EP1003530A4 EP97938483A EP97938483A EP1003530A4 EP 1003530 A4 EP1003530 A4 EP 1003530A4 EP 97938483 A EP97938483 A EP 97938483A EP 97938483 A EP97938483 A EP 97938483A EP 1003530 A4 EP1003530 A4 EP 1003530A4
Authority
EP
European Patent Office
Prior art keywords
thyroid hormone
eye treatments
synthetic thyroid
hormone compositions
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP97938483A
Other languages
English (en)
French (fr)
Other versions
EP1003530A1 (de
Inventor
Daniel M Schwartz
John D Baxter
Michele D Jumper
Thomas S Scanlan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California filed Critical University of California
Publication of EP1003530A1 publication Critical patent/EP1003530A1/de
Publication of EP1003530A4 publication Critical patent/EP1003530A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
EP97938483A 1996-08-20 1997-08-20 Synthetische schildrüssenhormone enthaltende zusammensetzungen zur augenbehandlung Withdrawn EP1003530A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2369796P 1996-08-20 1996-08-20
US23697P 1996-08-20
PCT/US1997/014691 WO1998007435A1 (en) 1996-08-20 1997-08-20 Eye treatments using synthetic thyroid hormone compositions

Publications (2)

Publication Number Publication Date
EP1003530A1 EP1003530A1 (de) 2000-05-31
EP1003530A4 true EP1003530A4 (de) 2001-10-04

Family

ID=21816699

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97938483A Withdrawn EP1003530A4 (de) 1996-08-20 1997-08-20 Synthetische schildrüssenhormone enthaltende zusammensetzungen zur augenbehandlung

Country Status (6)

Country Link
US (3) US6054485A (de)
EP (1) EP1003530A4 (de)
JP (2) JP3345428B2 (de)
KR (1) KR100405285B1 (de)
CA (1) CA2260992C (de)
WO (1) WO1998007435A1 (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6266622B1 (en) * 1995-12-13 2001-07-24 Regents Of The University Of California Nuclear receptor ligands and ligand binding domains
WO1997021993A2 (en) 1995-12-13 1997-06-19 The Regents Of The University Of California Nuclear receptor ligands and ligand binding domains
US20020143284A1 (en) * 2001-04-03 2002-10-03 Hosheng Tu Drug-releasing trabecular implant for glaucoma treatment
US7163918B2 (en) * 2000-08-22 2007-01-16 New River Pharmaceuticals Inc. Iodothyronine compositions
FR2816633B1 (fr) * 2000-11-10 2003-02-07 Lipha Methode de criblage d'agents susceptibles de traiter l'obesite
US7470659B2 (en) * 2001-12-07 2008-12-30 The Regents Of The University Of California Methods to increase reverse cholesterol transport in the retinal pigment epithelium (RPE) and Bruch's membrane (BM)
US20030162758A1 (en) * 2001-12-07 2003-08-28 Schwartz Daniel M. Treatment for age-related macular degeneration (AMD)
US20030229062A1 (en) * 2001-12-07 2003-12-11 The Regents Of The University Of California Treatments for age-related macular degeneration (AMD)
US7018646B2 (en) * 2002-05-30 2006-03-28 Van Dalen Johan T W Apparatus and method for delivering controlled quantities of one or more agents to the eye
US20050048099A1 (en) * 2003-01-09 2005-03-03 Allergan, Inc. Ocular implant made by a double extrusion process
US20040216749A1 (en) * 2003-01-23 2004-11-04 Hosheng Tu Vasomodulation during glaucoma surgery
US6969514B2 (en) * 2003-02-05 2005-11-29 Soll David B Method for treating elevated intraocular pressure, including glaucoma
WO2005051298A2 (en) 2003-11-19 2005-06-09 Metabasis Therapeutics, Inc. Novel phosphorus-containing thyromimetics
US7922702B2 (en) 2004-07-02 2011-04-12 Qlt Inc. Treatment medium delivery device and methods for delivery of such treatment mediums to the eye using such a delivery device
CA2606499C (en) 2005-05-26 2017-06-13 Metabasis Therapeutics, Inc. Thyromimetics for the treatment of fatty liver diseases
MX2007014501A (es) * 2005-05-26 2008-02-07 Metabasis Therapeutics Inc Tiromimeticos novedosos que contienen acido fosfinico.
US20060292194A1 (en) * 2005-06-24 2006-12-28 Thomas Lavin Treatment for burns and adipose deposits using thyroid hormone compound in a human
US20080000473A1 (en) * 2005-12-29 2008-01-03 Hugo Stephenson pH-Based Methods and Devices for Preventing Hemagglutinin Cell Membrane Fusion
JP2009532132A (ja) 2006-03-31 2009-09-10 キューエルティー プラグ デリバリー，インク． 薬物治療用鼻涙排液系インプラント
FR2924722B1 (fr) * 2007-12-10 2013-10-25 Oreal Procede de selection d'agents pour modifier la forme du cheveu et utilisation cosmetique des actifs.
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
US10307292B2 (en) 2011-07-18 2019-06-04 Mor Research Applications Ltd Device for adjusting the intraocular pressure
TWI775096B (zh) * 2012-05-15 2022-08-21 澳大利亞商艾佛蘭屈澳洲私營有限公司 使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd)
JP2016517883A (ja) 2013-05-03 2016-06-20 オレゴン ヘルス アンド サイエンス ユニバーシティー Ｘ連鎖副腎白質ジストロフィーの処置におけるソベチロムの使用
WO2015120115A1 (en) * 2014-02-05 2015-08-13 The Board Of Regents Of The University Of Oklahoma Compositions for treating retinal degeneration and methods of production and use thereof
CA2942776C (en) 2014-03-17 2023-01-24 Adverum Biotechnologies, Inc. Polyneucleotide cassette and expression vector for expression of a gene in cone cells using truncated m-opsin promoter
KR20170137730A (ko) 2015-03-02 2017-12-13 애드베룸 바이오테크놀로지스, 인코포레이티드 망막 추상체에 폴리뉴클레오타이드의 유리체 내 전달을 위한 조성물 및 방법
EP3265552B1 (de) * 2015-03-04 2021-12-29 President and Fellows of Harvard College Fluidische vorrichtung zur quantifizierung der dynamischen permeabilität und hydraulischen leitfähigkeit lebender gewebeschichten
GB2545763A (en) 2015-12-23 2017-06-28 Adverum Biotechnologies Inc Mutant viral capsid libraries and related systems and methods
KR20190104524A (ko) 2016-11-21 2019-09-10 바이킹 테라퓨틱스 인코포레이티드 당원축적질환의 치료 방법
KR102600115B1 (ko) 2017-06-05 2023-11-09 바이킹 테라퓨틱스 인코포레이티드 섬유증 치료를 위한 조성물
EP3768690A4 (de) 2018-03-22 2021-11-24 Viking Therapeutics, Inc. Kristalline formen und verfahren zur herstellung kristalliner formen einer verbindung
CN113423684A (zh) 2018-12-12 2021-09-21 速通医疗公司 新型拟甲状腺素药
CA3130371A1 (en) 2019-03-01 2020-09-10 Autobahn Therapeutics, Inc. Novel thyromimetics
WO2021173999A1 (en) * 2020-02-28 2021-09-02 Northwestern University Method of enhancing aqueous humor outflow and reducing intraocular pressure

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995017178A1 (en) * 1993-12-22 1995-06-29 The Regents Of The University Of California Use of non-steroidal cyclooxygenase inhibitors to treat elevated intraocular pressure
WO1997021993A2 (en) * 1995-12-13 1997-06-19 The Regents Of The University Of California Nuclear receptor ligands and ligand binding domains

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2798053A (en) * 1952-09-03 1957-07-02 Goodrich Co B F Carboxylic polymers
US4038264A (en) * 1974-01-07 1977-07-26 National Patent Development Corporation Hema copolymers having high oxygen permeability
US4192827A (en) * 1974-06-27 1980-03-11 Ciba-Geigy Corporation Water-insoluble hydrophilic copolymers
US4136250A (en) * 1977-07-20 1979-01-23 Ciba-Geigy Corporation Polysiloxane hydrogels
US4548990A (en) * 1983-08-15 1985-10-22 Ciba-Geigy Corporation Crosslinked, porous polymers for controlled drug delivery
CN1011118B (zh) * 1986-06-13 1991-01-09 天津医学院附属医院 治疗白内障的眼药水的制药方法
FR2601247A1 (fr) * 1986-07-09 1988-01-15 Merk Sharp Dohme Chibret Labor Combinaison d'agents beta-bloquants et de pilocarpine.
US5360399A (en) * 1992-01-10 1994-11-01 Robert Stegmann Method and apparatus for maintaining the normal intraocular pressure
US6221911B1 (en) 1995-06-07 2001-04-24 Karo Bio Ab Uses for thyroid hormone compounds or thyroid hormone-like compounds
AU6476996A (en) * 1995-06-07 1996-12-30 Karo Bio Ab Novel uses for thyroid hormones or thyroid hormone-like comp ounds
US6380255B1 (en) 1995-06-07 2002-04-30 Karo Bio Ab Treatment for dermal skin atrophy using thyroid hormone compounds or thyroid hormone-like compounds

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995017178A1 (en) * 1993-12-22 1995-06-29 The Regents Of The University Of California Use of non-steroidal cyclooxygenase inhibitors to treat elevated intraocular pressure
WO1997021993A2 (en) * 1995-12-13 1997-06-19 The Regents Of The University Of California Nuclear receptor ligands and ligand binding domains

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
HALLMAN, VIVIENNE L.: "Effect of thyroid hormones on intraocular pressure", EXP. EYE RES. (1967), 6(3), 219-26, XP001002983 *
See also references of WO9807435A1 *
SMITH K.D. ET AL: "An association between hypothyroidism and primary open-angle glaucoma.", OPHTHALMOLOGY, (1993) 100/10 (1580-1584)., XP001016291 *
YONEYAMA, JOJI: "Effects of antiglaucoma agents on glycosaminoglycans in organ-cultured rabbit trabecular meshwork", OPHTHALMOLOGICA (1994), 208(5), 278-83, XP002174077 *

Also Published As

Publication number Publication date
EP1003530A1 (de) 2000-05-31
WO1998007435A1 (en) 1998-02-26
CA2260992A1 (en) 1998-02-26
AU4079397A (en) 1998-03-06
KR100405285B1 (ko) 2003-11-12
CA2260992C (en) 2004-03-09
AU717608B2 (en) 2000-03-30
US20030175849A1 (en) 2003-09-18
US7122579B2 (en) 2006-10-17
JP3345428B2 (ja) 2002-11-18
JP2002348249A (ja) 2002-12-04
US6555582B1 (en) 2003-04-29
KR20000068213A (ko) 2000-11-25
JP2001500964A (ja) 2001-01-23
US6054485A (en) 2000-04-25

Similar Documents

Publication Publication Date Title
EP1003530A4 (de) Synthetische schildrüssenhormone enthaltende zusammensetzungen zur augenbehandlung
EG20753A (en) Synergistic composition
CY2506B1 (en) Composition
GB9308103D0 (en) Cosmetic composition
ZA951012B (en) Composition
GB9624874D0 (en) Composition
GB9601398D0 (en) Composition
GB9612595D0 (en) Composition
GB9605247D0 (en) Composition
EP0884044A4 (de) Haarbehandlungsmittel
GB9619074D0 (en) Composition
GB9600604D0 (en) Composition
ZA982863B (en) Synergistic fungicadal composition
GB9602266D0 (en) Composition
GB9415810D0 (en) Composition
GB9610966D0 (en) Composition
PL330421A1 (en) Antiprespirant composition
ZA97698B (en) Composition
GB9410139D0 (en) Hebicidal composition
ZA97146B (en) Composition
GB9625040D0 (en) Composition
GB9622692D0 (en) Composition
GB9625479D0 (en) Composition
HU9603006D0 (en) Ophthalmologie composition
GB9604945D0 (en) Composition

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19990315

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RIC1 Information provided on ipc code assigned before grant

Free format text: 7A 61K 33/36 A, 7A 61K 49/00 B, 7A 61K 31/195 B

A4 Supplementary search report drawn up and despatched

Effective date: 20010820

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20020909

17Q First examination report despatched

Effective date: 20020909

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20080206